SCHEMBL4508403

SCHEMBL4508403

NCCCc1cn2c(=O)[nH]nc2c2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.40
GSK3A P49840 13/20 0.37
GSK3B P49841 13/20 0.37
LTK P29376 2/20 0.37
ALK Q9UM73 2/20 0.37
DYRK1B Q9Y463 2/20 0.37
RET P07949 1/20 0.37
MET P08581 1/20 0.37
GRK5 P34947 1/20 0.37
CDK8 P49336 1/20 0.37
RPS6KA3 P51812 1/20 0.37
MST1R Q04912 1/20 0.37
TYRO3 Q06418 1/20 0.37
DYRK1A Q13627 1/20 0.37
LRRK2 Q5S007 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
PDE5A O76074 1/20 0.36
CAMK2D Q13557 1/20 0.36
DAPK3 O43293 1/20 0.35
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4506538 0.87 CHEK1 (0.38) CHEK1GSK3AGSK3BLTKALK
SCHEMBL13920080 0.86 PBRM1 (0.42) GSK3AGSK3BLTKALKDYRK1B
SCHEMBL4511564 0.86 POLB (0.40) CHEK1GSK3AGSK3BLTKALK
SCHEMBL4511775 0.84 CHEK1 (0.46) CHEK1GSK3AGSK3B
SCHEMBL4241608 0.83 GSK3A (0.44) GSK3AGSK3B
SCHEMBL13933585 0.81 LTK (0.44) CHEK1GSK3AGSK3BLTKALK
SCHEMBL4517371 0.81 GSK3A (0.43) GSK3AGSK3B
SCHEMBL4493617 0.81 HTR1B (0.43) CHEK1GSK3AGSK3BLTKALK
SCHEMBL4247437 0.80 GSK3B (0.34) CHEK1GSK3AGSK3BMPO
SCHEMBL4061355 0.79 PDE5A (0.38) CHEK1GSK3AGSK3BLTKALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
WO-2007127138-A1 TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-11-08 WO disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254879-A1 Inhibitors of checkpoint kinases CHEK1, CHEK2, PLK1 CHEK1 1/4885GSK3A 226/4885GSK3B 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.